Eosinophilic Oesophagitis is a lifelong disease affecting the oesophagus, the tube connecting the mouth and stomach. Too many eosinophils, a type of white blood cell, in the oesophagus, causes inflammation, making swallowing difficult.

Although this condition has no cure, proper therapy can help manage symptoms. However, finding the right therapy can be challenging due to the lack of licensed treatment options available.

In 2018, Jorveza Budesonide oral dissolvable tablet was the first EoE treatment approved for use in Europe and has since been approved in Australia and Canada

In May of 2022, the FDA approved its first USA treatment for eosinophilic esophagitis, a biological agent called Dupilumab and has since been approved in the EU. It is used to suppress the allergic arm of the immune system and treat patients with EoE that is mainly moderate to severe.

Access to these treatments depends on your age, location and other factors, currently leaving many sufferers still with off-label medications that are designed for other conditions such as asthma.

In this FAQ CEGIR provides information on potential EoE treatment options currently undergoing investigation. If proven to be both effective and safe, they may become viable treatment options in the future.

What Treatments For EoE Are Being Investigated

Multiple treatments for EoE are being investigated at different phases of the clinical trial approval process.​

Dupilumab (anti-IL-4r𝛼), phase III (1-11 yrs)​

  • Monoclonal antibody that binds to the IL-4 receptor 𝛼-subunit inhibiting signalling of IL-4 and IL-13, two cytokines that play a critical role in allergic inflammation.​

  • FDA-approved for atopic dermatitis (ages 6+ mths), moderate-to-severe asthma (eosinophilic or oral steroid-dependent, ages 6+ yrs), chronic rhinosinusitis (ages 18+ yrs), eosinophilic oesophagitis (EoE) (ages 12+ yrs and weighing ≥ 40 kg), prurigo nodularis (ages 18+ yrs)​

Cendakimab (anti-IL-13) – phase III (12-75 yrs)​

  • Monoclonal antibody that binds to and neutralizes IL-13, a cytokine that plays a key role in EoE.​

Tezepelumab (anti-TLSP) – phase III (12-80 yrs)​

  • Monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a cytokine released by the epithelium that plays an important role in starting allergic inflammation.​

  • FDA-approved for add-on maintenance treatment for severe asthma (ages 12+ yrs)​

Lirentelimab (anti-Siglec-8) – phase II/III (12-80 yrs)​

  • Monoclonal antibody that binds to the inhibitory receptor Siglec-8, causing eosinophil death and inhibiting mast cells.​

Etrasimod (SP1R modulator) – phase II (18-65 yrs)​

  • Small molecule that modulates the sphingosine-1-phosphate receptor and inhibits trafficking of lymphocytes from the lymph nodes into the blood.

Information is provided by The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Learn more about CEGIRs work

Donate today for a brighter tomorrow

Last updated 21/09/23 ©EOS Network 2023 All rights reserved

​

Published:

Updated:

Author: Olena Filatova

Share this page